(R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2-苯基乙酸酯 (R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2-苯基乙酸酯
CAS 1206695-46-6 MFCD306695466
化学结构图
SMILES:
别名和识别编码
| Chemical Name Translation | (R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2-苯基乙酸酯 |
|---|
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
相关文献及参考
- [2]. Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats
- [3]. Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr;101(8):1036-42.
- [4]. Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96.
- [1]. Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18.
- [1]. Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18.
- [2]. Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic
京ICP备2020036287号